EEG Analysis and Animal Behavior in CNS Drug Development
About this webinar
EEG analysis (Electroencephalography) is becoming a promising translatable biomarker for predicting the likelihood that novel therapies and compounds will exhibit clinical efficacy early in preclinical development.
EEG and relevant analyses have been very useful in the drug development process in the context of several major central nervous system (CNS) diseases including Alzheimer’s disease, epilepsy, sleep/wake disorders, schizophrenia, depression, attention deficit, hyperactivity disorder and pain.
Additionally, EEG-based signatures represent promising preclinical screens to quickly determine CNS penetration, drug-target engagement, evidence of efficacy, pharmacokinetic/pharmacodynamic profile, CNS safety and toxicity and pro-convulsant risk.
In this webinar, the featured speaker will review the EEG analysis, related optimization parameters and candidate compound selection as well as case studies where EEG-based signatures in correlation with animal behavior could validate the EEG as the endpoint for a set of translatable biomarkers bridging preclinical and clinical programs.
Join this webinar to gain insights into EEG analysis as physiological endpoints to facilitate drug discovery for CNS diseases.
Who should attend
- CNS drug discovery and development
- Alzheimer’s disease, epilepsy, sleep/wake disorders, schizophrenia, depression, attention deficit, hyperactivity disorder and pain
- CNS penetration, drug-target engagement, evidence of efficacy, pharmacokinetic/pharmacodynamic profile, CNS safety and toxicity and pro-convulsant risk
What you will learn
- Electroencephalography (EEG) analysis as physiological endpoints to facilitate drug discovery, lead optimization, or candidate compound selection as well as to serve for go/no go decisions
- Case studies of EEG-based signatures in correlation with animal behavior which potentially may validate the EEG as endpoints for a set of translatable biomarkers bridging preclinical and clinical programs
Featured Speakers
Ruiben Feng, PhD
Dr. Ruiben Feng, Executive Director of the Neurobiology and Neuropharmacology department, has extensive experience in CRO drug development and manages the team supporting global CNS drug discovery and development at Shanghai ChemPartner.
Dr. Feng received his PhD in Physiology from East China Normal University and has significant expertise in CNS drug discovery and development for neurodegeneration, epilepsy, pain, sleep and anesthetics and mood disorders. Additionally, he has extensive experience in the management of animal care and use (IACUC) and environment, health and occupational safety (EHS).
Partner for this event
ChemPartner
Shanghai ChemPartner, which includes ChemPartner and ChemPartner Biologics, is a CRO/CDMO offering a broad range of drug discovery, development, and manufacturing services.
ChemPartner is a science-based, technology-driven global CRO and CDMO offering a broad range of services including discovery chemistry, biology, pharmacology, DMPK, and exploratory toxicology as well as biologics discovery, CMC development, and manufacturing.
ChemPartner serves a diverse global client base as more and more pharmaceutical and biotech companies look for alliance partners to provide intellectual contributions and exceptional technical expertise. With locations and representatives in China, Europe, and the US, ChemPartner is uniquely positioned to be a true biopharmaceutical alliance partner.
